Treatment News : Those With Both HIV and Hepatitis C Face High Liver Cancer Rates

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 19, 2014

Those With Both HIV and Hepatitis C Face High Liver Cancer Rates

HIV ramps up liver disease progression among those coinfected with hepatitis C virus (HCV), even in the face of antiretroviral (ARV) treatment for HIV, MedPage Today reports. Publishing their findings in Annals of Internal Medicine, researchers at the Perelman School of Medicine at the University of Pennsylvania analyzed data on 4,280 coinfected people taking ARVs and 6,079 hep C monoinfected people receiving medical care between 1997 and 2010.

Among the coinfected study participants, there were 271 cases (6.3 percent) of decompensated cirrhosis, compared with 305 cases (5.0 percent) among the monoinfected group. After adjusting for various factors, the researchers calculated that those coinfected with HIV and HCV had a 56 percent greater likelihood of decompensated cirrhosis when compared with the monoinfected group. Those with a HIV viral load above 1,000 had a 59 percent greater risk of advanced liver disease compared with the monoinfected participants, while those with a lower viral load had a 44 percent greater risk.

“Our results suggest that serious consideration should be given to initiating hepatitis C treatment in patients coinfected with HIV and hepatitis C—particularly among those with advanced liver fibrosis or cirrhosis—in order to try to reduce the risk of serious, potentially life-threatening liver complications,” Vincent Lo Re III, MD, MSCE, an assistant professor of medicine at Penn and the study’s lead author, said in a release. “By taking action sooner, we may be able to reduce the risk of advanced liver disease in coinfected patients.”

Because the study was mainly comprised of men, the findings are not necessarily applicable to women.

To read the MedPage Today story, click here.

To read the study abstract, click here.

Search: HIV, hepatitis C, virus, hep C, HCV, coinfection, liver disease, decompensated cirrhosis, Vincent Lo Re III, University of Pennsylvania.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.